Fig. 4

Survival of patients with de novo UTUC after renal transplantation stratified by AA exposure or conversion to mTOR inhibitor. A No statistical difference was observed in UTUC-free survival stratified by AA exposure; B No statistical difference was observed in OS stratified by AA exposure; C No statistical difference was observed in CSS stratified by AA exposure; D No statistical difference was observed in bladder RFS stratified by AA exposure; E The contralateral upper tract RFS rate in AA group was lower than that in non-AA group (p = 0.017); F No statistical difference was observed in OS stratified by conversion to mTOR inhibitor; G No statistical difference was observed in CSS stratified by conversion to mTOR inhibitor. UTUC Upper tract urothelial carcinoma; OS Overall survival, CSS Cancer-specific survival, RFS Recurrence-free survival, AA Aristolochic acid, mTOR Mammalian target of rapamycin